|
ASP Isotopes Inc. to host institutional investor access event in South Africa from November 11 – 13, 2025
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASP ISOTOPES INC. TO HOST INSTITUTIONAL INVESTOR ACCESS EVENT IN SOUTH AFRICA FROM NOVEMBER 11 – 13, 2025
*** Limited places remain available for institutional investors for this previously announced Investor Access
Event ***
Washington, D.C., October 10, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP
Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology
and processes for the production of isotopes for use in multiple industries, today announced that it will host
an Institutional Investor Access Event in South Africa from November 11-13, 2025.
**There is also the possibility of adding an extra day to the trip and visiting the Renergen Virginia
Gas Project on November 14th – please let us know if you are also interested in attending that day
too. (subject to numbers)**
All investors are invited to request a registration to attend the Institutional Investor Access Event.
ASP Isotopes values transparency and open communication with all stakeholders and counterparties.
During 2024, the Company welcomed over 60 investors and corporate clients to its facilities in South Africa,
and have already hosted a highly successful event for Investors in January and June 2025 with
approximately 50 investors from 3 continents.
Investors are responsible for their own flight and hotel expenses.
The timing of the event for investors departing from the USA allows for the following:
Mon, November 10 (evening) Depart USA
Tues, November 11 (evening) Arrive in South Africa
Wed, November 12 (all day) Scientific Sessions and Plant Tours
Thurs, November 13 (all day) Scientific Sessions and Plant Tours
Thurs, November 13 (evening) Depart South Africa
Fri, November 14 (morning) Arrive in USA
Stakeholders wishing to attend should email Viktor Petkov at vpetkov@aspisotopes.com as soon as
possible to complete the registration process and receive confirmation of your place. Attendees will be
required to submit a copy of their passport by October 21, 2025 in order to obtain the required security
clearances to visit the Company's secure facilities. For citizens of the USA, UK and Europe, security
clearance is typically an expedient process. For other nationalities (including dual nationalities), a longer
period of time may be required. Registrations for the event are subject to availability and to acceptance by
the Company at its absolute discretion.
This trip will allow you to see firsthand the progress being made on all ASP's enrichment production plants,
as well as hear future plans and strategy for 2026. You will have a chance to meet the management and
scientific team behind these innovative technologies. There will be extensive presentations and
opportunities for Q&A.
Participants of the Investor Access Event will be able to visit all three facilities, as well as PET Labs, the
Company's radioisotope production centre.
ASP Isotopes looks forward to welcoming as many stakeholders as possible for them to see firsthand all
our facilities and hear directly from the Scientific and Engineering Teams.
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of
technology and processes to produce isotopes for use in multiple industries. The Company employs
proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial
focus is on producing and commercializing highly enriched isotopes for the healthcare and technology
industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum
Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in
Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light
isotopes).
There is a growing demand for isotopes such as Silicon-28 for enabling quantum computing; Molybdenum-
100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as
well as Chlorine-37, Lithium-6, Lithium-7 and Uranium-235 for green energy applications. The ASP
Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass
molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions
of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,
expectations, and assumptions regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy, and other future conditions. Forward-looking
statements can be identified by words such as "believes," "plans," "anticipates," "expects," "estimates,"
"projects," "will," "may," "might," and words of a similar nature. Examples of forward-looking statements
include, among others but are not limited to, statements we make regarding expected operating results,
such as future revenues and prospects from the potential commercialization of isotopes, future performance
under contracts, and our strategies for product development, engaging with potential customers, market
position, and financial results. Because forward-looking statements relate to the future, they are subject to
inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are
outside our control. Our actual results, financial condition, and events may differ materially from those
indicated in the forward-looking statements based upon a number of factors. Forward-looking statements
are not a guarantee of future performance or developments. You are strongly cautioned that reliance on
any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you
should not rely on any of these forward-looking statements. There are many important factors that could
cause our actual results and financial condition to differ materially from those indicated in the forward-
looking statements, including the outcomes of various strategies and projects undertaken by the Company;
the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or
elsewhere; our reliance on the efforts of third parties; our ability to complete the construction and
commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the
Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution
of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete
certain transactions and realize anticipated benefits from acquisitions; contracts, dependence on our
Intellectual Property (IP) rights, certain IP rights of third parties; and the competitive nature of our industry.
Any forward-looking statement made by us in this press release is based only on information currently
available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new information, future developments or
otherwise. This press release includes market and industry data and forecasts that we obtained from
internal research, publicly available information and industry publications and surveys. Industry publications
and surveys generally state that the information contained therein has been obtained from sources believed
to be reliable. Unless otherwise noted, statements as to our potential market position relative to other
companies are approximated and based on third-party data and internal analysis and estimates as of the
date of this press release. We have not independently verified this information, and it could prove
inaccurate. Industry and market data could be wrong because of the method by which sources obtained
their data and because information cannot always be verified with certainty due to the limits on the
availability and reliability of raw data, the voluntary nature of the data-gathering process and other
limitations and uncertainties. In addition, we do not know all of the assumptions regarding general economic
conditions or growth that were used in preparing the information and forecasts from sources cited herein.
No information in this press release should be interpreted as an indication of future success, revenues,
results of operation, or stock price. All forward-looking statements herein are qualified by reference to the
cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
10 October 2025
Sponsor
Valeo Capital Proprietary Limited
Date: 10-10-2025 03:57:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS. |
|
